Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.01.010Source: DataRank Database

Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression is a research paper published in Clinical Lung Cancer (2021). On theSindex it has a DataRank of 0. It has been cited 42 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access42 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 4.17)OA: greenTopics (62)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Zofia Piotrowska ORCID,Kevin Stirling ORCID,Stephen V. Liu ORCID,Mandeep K. Banwait ORCID,Kristen Cunanan ORCID

Live enrichment

PubMed:33610453 PMC:PMC8205932 OpenAlex:https://openalex.org/W3122379944

NCI NIH HHS

Grant: R01 CA137008

National Institutes of Health

Grant: 2R01CA137008-06

Impact of heterogeneity on response to EGFR T790M inhibitors

National Institutes of Health

FWCI

4.17

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8205932

publisherhttps://api.elsevier.com/content/article/PII:S1525730421000139?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1525730421000139?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cllc.2021.01.010

Fields of Study

Lung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

AcrylamidesAdultAgedAged, 80 and overAniline CompoundsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungFemaleHumansIndolesLung NeoplasmsMaleMiddle AgedMutationPyrimidinesRetrospective StudiesCohort StudiesSurvival RateTreatment OutcomeDisease ProgressionErbB Receptors

Keywords

OsimertinibMedicineChemotherapyOncologyInternal medicineLung cancerChemotherapy regimenCancerEpidermal growth factor receptorErlotinibEGFRCombination therapyBrain metastasesTargeted TherapyEgfr Tyrosine Kinase InhibitorAdultAged, 80 and overMaleAcrylamidesAniline CompoundsLung NeoplasmsIndolesMiddle AgedCohort StudiesErbB ReceptorsSurvival RateTreatment OutcomeCarcinoma, Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsMutationDisease ProgressionHumansFemaleAgedRetrospective Studies

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression

FAIR Checklist

Authors (10)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)